Free Trial

Q3 Earnings Forecast for MRVI Issued By KeyCorp

Maravai LifeSciences logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • KeyCorp forecasts a Q3 2027 loss of $0.05 per share for Maravai LifeSciences, maintaining an “Overweight” rating and an $11 price target.
  • Analysts’ consensus is “Moderate Buy,” with an average target price of $8.10; ratings range from Strong Buy to Sell.
  • In its latest reported quarter, Maravai posted a loss of $0.03 per share, beating the $0.06 loss consensus, and revenue of $45.85 million, above estimates of $43.56 million.
  • MarketBeat previews the top five stocks to own by December 1st.

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Free Report) - KeyCorp issued their Q3 2027 earnings estimates for Maravai LifeSciences in a note issued to investors on Wednesday, November 11th. KeyCorp analyst P. Knight forecasts that the company will earn ($0.05) per share for the quarter. KeyCorp currently has an "Overweight" rating and a $11.00 target price on the stock. The consensus estimate for Maravai LifeSciences' current full-year earnings is ($0.16) per share.

A number of other equities analysts have also commented on MRVI. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Maravai LifeSciences in a research report on Wednesday, August 26th. Wells Fargo & Company boosted their price target on Maravai LifeSciences from $5.50 to $6.50 and gave the company an "overweight" rating in a report on Friday, August 7th. UBS Group boosted their price target on Maravai LifeSciences from $2.50 to $8.00 and gave the company a "neutral" rating in a report on Wednesday, September 9th. TD Cowen began coverage on Maravai LifeSciences in a research note on Monday, October 5th. They issued a "buy" rating and a $9.00 price objective on the stock. Finally, Wall Street Zen upgraded Maravai LifeSciences from a "hold" rating to a "buy" rating in a report on Saturday, November 7th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, Maravai LifeSciences presently has a consensus rating of "Moderate Buy" and a consensus target price of $8.10.

Read Our Latest Report on MRVI

Maravai LifeSciences Price Performance

Maravai LifeSciences stock opened at $7.54 on Monday. The company has a debt-to-equity ratio of 0.51, a current ratio of 4.66 and a quick ratio of 3.35. The stock has a market cap of $1.96 billion, a price-to-earnings ratio of -17.53 and a beta of 0.61. The firm has a 50-day moving average of $7.40 and a two-hundred day moving average of $5.43. Maravai LifeSciences has a 1 year low of $2.80 and a 1 year high of $9.42.

Maravai LifeSciences (NASDAQ:MRVI - Get Free Report) last posted its quarterly earnings results on Wednesday, November 4th. The company reported ($0.03) EPS for the quarter, topping the consensus estimate of ($0.06) by $0.03. Maravai LifeSciences had a negative net margin of 30.83% and a negative return on equity of 12.44%. The company had revenue of $45.85 million for the quarter, compared to the consensus estimate of $43.56 million.

Institutional Trading of Maravai LifeSciences

A number of hedge funds have recently added to or reduced their stakes in the business. Royal Bank of Canada grew its holdings in Maravai LifeSciences by 49.0% during the 1st quarter. Royal Bank of Canada now owns 9,761 shares of the company's stock worth $27,000 after acquiring an additional 3,209 shares in the last quarter. State of Alaska Department of Revenue bought a new stake in shares of Maravai LifeSciences in the 3rd quarter valued at about $47,000. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Maravai LifeSciences in the 3rd quarter valued at about $58,000. Pictet Asset Management Holding SA purchased a new stake in shares of Maravai LifeSciences in the 3rd quarter worth approximately $78,000. Finally, Landscape Capital Management L.L.C. purchased a new stake in shares of Maravai LifeSciences in the 3rd quarter worth approximately $79,000. 50.25% of the stock is owned by hedge funds and other institutional investors.

Maravai LifeSciences Company Profile

(Get Free Report)

Maravai LifeSciences provides products and services used by biotechnology and pharmaceutical companies in the development and production of therapeutics, vaccines, and other biologic products. Its offerings include specialized nucleic acid materials and analytical testing services that support research, manufacturing, and quality control. Through TriLink BioTechnologies, the company supplies modified nucleotides, custom RNA and DNA, and related materials used in applications such as messenger RNA research and production.

Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Maravai LifeSciences Right Now?

Before you consider Maravai LifeSciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Maravai LifeSciences wasn't on the list.

While Maravai LifeSciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines